BioMarin Pharmaceutical Inc.
BMRN
$67.48
-$0.84-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.65% | 28.28% | 19.61% | 8.79% | 20.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.65% | 28.28% | 19.61% | 8.79% | 20.22% |
| Cost of Revenue | -1.30% | 47.18% | 2.03% | 7.43% | -54.03% |
| Gross Profit | 20.24% | 22.94% | 38.46% | 10.23% | 114.01% |
| SG&A Expenses | -34.19% | 17.48% | 27.62% | 7.05% | 16.51% |
| Depreciation & Amortization | -36.66% | -68.06% | -8.48% | -8.76% | -2.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.82% | 14.71% | 11.68% | 6.81% | 14.95% |
| Operating Income | 842.98% | 273.11% | 83.71% | 25.73% | 3,131.00% |
| Income Before Tax | 777.73% | 222.64% | 86.61% | 85.96% | 210.08% |
| Income Tax Expenses | 4,364.89% | 2,096.82% | 69.00% | 185.94% | 93.95% |
| Earnings from Continuing Operations | 513.22% | 162.72% | 91.25% | 74.35% | 8,282.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 513.22% | 162.72% | 91.25% | 74.35% | 8,282.73% |
| EBIT | 842.98% | 273.11% | 83.71% | 25.73% | 3,131.00% |
| EBITDA | 418.73% | 136.43% | 61.47% | 19.12% | 128.89% |
| EPS Basic | 506.11% | 159.72% | 89.03% | 72.32% | 8,415.38% |
| Normalized Basic EPS | 1,257.41% | 218.79% | 84.46% | 36.06% | 215.76% |
| EPS Diluted | 644.69% | 160.67% | 87.65% | 72.16% | 655.13% |
| Normalized Diluted EPS | 1,239.68% | 212.92% | 81.45% | 34.27% | 210.34% |
| Average Basic Shares Outstanding | 1.17% | 1.17% | 1.15% | 1.18% | 1.32% |
| Average Diluted Shares Outstanding | 2.47% | 3.12% | 2.82% | 2.52% | 3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
